Bacterial Pneumonia Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Efficacy, Safety, Tolerability of Carbavance Compared to Best Available Therapy in Serious Infections Due to Carbapenem Resistant Enterobacteriaceae, in Adults
Conditions: Urinary Tract Infection Complicated; Acute Pyelonephritis; Hospital Acquired Bacterial Pneumonia; Ventilator-associated Bacterial Pneumonia; BacteremiaInterventions: Drug: Carbavance; Drug: Best Available TherapySponsors: Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company); Department of Health and Human ServicesRecruiting - verified October 2014 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 18, 2014 Category: Research Source Type: clinical trials

Efficacy, Safety, Tolerability of Carbavance Compared to Best Available Therapy in Serious Infections Due to Carbapenem Resistant Enterobacteriaceae, in Adults
Conditions: Urinary Tract Infection Complicated; Acute Pyelonephritis; Hospital Acquired Bacterial Pneumonia; Ventilator-associated Bacterial Pneumonia; BacteremiaInterventions: Drug: Carbavance; Drug: Best Available TherapySponsors: Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company); Department of Health and Human ServicesRecruiting - verified January 2015 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 18, 2014 Category: Research Source Type: clinical trials

Efficacy, Safety, Tolerability of Carbavance Compared to Best Available Therapy in Serious Infections Due to Carbapenem Resistant Enterobacteriaceae, in Adults
Conditions: Urinary Tract Infection Complicated; Acute Pyelonephritis; Hospital Acquired Bacterial Pneumonia; Ventilator-associated Bacterial Pneumonia; BacteremiaInterventions: Drug: Carbavance; Drug: Best Available TherapySponsors: Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company); Department of Health and Human ServicesRecruiting - verified September 2014 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 18, 2014 Category: Research Source Type: clinical trials

Efficacy and Safety Study of Intravenous to Oral Solithromycin (CEM-101) Compared to Intravenous to Oral Moxifloxacin in Treatment of Patients With Community-Acquired Bacterial Pneumonia
Condition: Community-acquired Bacterial PneumoniaInterventions: Drug: Solithromycin; Drug: MoxifloxacinSponsor: Cempra PharmaceuticalsRecruiting - verified October 2014 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 23, 2013 Category: Research Source Type: clinical trials